Avidity: FDA Eases Partial Clinical Hold On AOC 1001 : vimar

Avidity Biosciences, Inc. (RNA) announced the FDA has eased the partial clinical hold on AOC 1001, allowing the company to double the number of participants in the MARINA Open-Label Extension study receiving 4 mg/kg of AOC 1001.

Related Keywords

Sarah Boyce , More Such Health News , Avidity Biosciences Inc , Avidity Biosciences , Label Extension , Fda , Avidity ,